GrowLab Organics

Idea

Introduction

GLO is a cooperatively owned cannabis company in the British Isles. We exist to support our patients so they can live better lives through the power of cannabis. We believe that no one should struggle to access cannabis as their medicine.

Challenge:

Over a million people are using cannabis in the UK daily but do so with the fear of criminalisation. Legally there is limited choice and the accessibility varies as wildly as the quality. The real experts are unable to find work within their specialism and corporations are leading the charge without considering the existing patient community. It’s time to end the struggle.

Solution:

GLO will look to offer choice by producing craft quality cannabis at a fair price, we'll do so with the community in our hearts, our ears and in our facilities. We grow with love for you.

Result:

Patients will be able to access the quality of medicine that they deserve. We envision specialists working with and for GLO, as well as the community as a whole benefitting from our growth as a co-operative.

Substantial accomplishments to date

Licenses:

GLO has been approved by the Isle of Man Government for cultivation, processing, finished products, import/export, R&D, and testing.

Community:

Exclusive partnership with Cancard.

Cancard is the largest cannabis patient group in Europe representing more than 75,000 members.

Product:

We're building a cutting-edge facility to produce our own differentiated flower and solventless products in the pipeline.

We'll look to enable access to licensed producers all over the world to find the best products patients want.

Technology:

Proprietary GLOchain provenance, production and supply chain control tool.

Ability to track all variables in production and use data to help patients, regulators and us.

Brand & Marketing:

Purpose and value-led organisation.

Comprehensive media and comms strategy lined up.

We have a documentary series being made about GLO which is currently being pitched to some national broadcasters.

Isle of Man:

We believe this is the ideal location to base a British cannabis company, part of British Isles, inside the Customs Union for trade, separate government and regulator to the UK.

Availability of power, water, land, low tax and good relationship with the government.

Monetisation strategy

Once the facility is built and production begins, we envisage GLO's primary source of revenue will come from selling medicinal cannabis in both expertly dried and cured flowers and also extracted forms using cutting-edge solventless techniques.

Within this, we will look to provide a range of strains and cultivars that broadly fall into four different chemovars or categories: high THC, medium THC, balanced THC:CBD, and high CBD.

We aim to achieve this both by importing 3rd party products and by creating our own products. Having a mix of manufactured and wholesale sales provides resilience in supply to meet demand changes, as well as increased choice for patients.

Trading 3rd party products is a light touch, lower margin revenue stream, whereas we calculate the margin on in-house production to be extremely attractive as the marginal cost of supply drops whilst the price does not.

We envisage that our initial customers will be GPhC-licensed pharmacists that dispense to patients holding prescriptions.

We believe our partnership with Cancard gives us a strategic advantage with our route to market.

Use of proceeds

Majority of funds are earmarked to build a first class cannabis facility, enabling us to produce the highest quality products using craft organic growing methods at scale.

The licenced facility on the Isle of Man will, at full capacity, operate 22 separate 200m2 flower rooms and 6 drying rooms, which we calculate will produce over 20 unique strains each year.

Our vision is for heat, energy and water to all be recovered and recycled within the facility, with even the plant stalks being turned into the product packaging.

GLO has built proprietary supply chain technology that will enable complete transparency for patients on how each plant has been grown and processed. This will also enable a feedback loop - providing unique insight for the wider medical community on the impact of different strains on symptoms and conditions.

In addition to the facility, which is a fixed asset, we plan to invest in exceptional talent to operate the business. During construction our team will remain lean, increasing only once we are actively cultivating.